All News

    SANRECO Trial Explores Divesiran for Polycythemia Vera Treatment

    November 24th 2025, 8:00pm

    Article

    The phase 2 SANRECO study has recently completed enrollment and will evaluate divesiran, a potential therapy for patients with polycythemia vera.

    Voranigo is Safe and Tolerable in High-Grade IDH-Mutant Gliomas

    November 24th 2025, 5:58pm

    Article

    Voranigo was safe and well tolerated in patients with grade 3 or 4 IDH-mutant gliomas, a type of brain cancer.

    Sac-TMT Combo Shows Benefit in Advanced Lung Cancer Treatment

    November 24th 2025, 5:00pm

    Article

    Sac-TMT plus Keytruda improved time without cancer growth in people with advanced lung cancer whose tumors show programmed death ligand 1.

    Imbruvica Plus Drug Combo Shows Strong Responses in Newly Diagnosed PCNSL

    November 24th 2025, 4:05pm

    Article

    Imbruvica plus R-MPV led to high response rates and was tolerable for patients with newly diagnosed primary central nervous system lymphoma.

    Expert Advice and Resources for Patients with Neuroendocrine Tumors

    November 24th 2025, 2:00pm

    Video

    Dr. Pamela L. Kunz sat down for an interview with CURE to discuss resources and ongoing initiatives that may help patients with this disease.

    Eflornithine Plus Gleostine Improves Progression, Survival In Some With Astrocytoma

    November 23rd 2025, 2:00pm

    Article

    Eflornithine plus Gleostine was associated with superior overall survival and progression-free survival in grade 3 IDH-mutated astrocytoma.

    B7-H3 CAR T-Cell Therapy Shows Acceptable Safety in Recurrent Glioblastoma

    November 22nd 2025, 3:55pm

    Article

    Intraventricular B7-H3 CAR T-cell therapy was well tolerated up to 1 x 10⁷ cells per infusion and showed early signs of activity in recurrent glioblastoma.

    Voranigo Plus Temodar Found to Be Safe in Patients With IDH1/2+ Glioma

    November 22nd 2025, 3:45pm

    Article

    Voranigo plus Temodar was safe in glioma with IDH1/2 mutations.

    Gomekli Shows Early Activity in Pediatric Low Grade Glioma

    November 22nd 2025, 2:10pm

    Article

    Early data from the SJ901 study show Gomekli generates responses with manageable side effects in children and young adults with low grade glioma.

    Early Real-World Uptake of Voranigo in Patients With IDH-Mutant Glioma

    November 21st 2025, 10:55pm

    Article

    Early data indicate Voranigo is rapidly being used in newly diagnosed and previously treated patients with IDH-mutant glioma, highlighting ongoing treatment needs.